---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-26-000055"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2026-08-05T20:01:16+00:00"
generated_at: "2026-08-05T20:02:06.645496+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xencor Q2 net loss $21.7M; Alexion settlement $105M; XmAb819 ESMO presentation

## Summary
- Q2 2026 revenue $51.2M (up from $43.6M YoY); net loss $21.7M ($0.29 loss per share) vs $30.8M loss in Q2 2025.
- Alexion settlement resolves Ultomiris royalty dispute: $105M total, first $52.5M due Aug 2026, second $52.5M in 2027; no further U.S. royalties.
- XmAb819 (ENPP3 x CD3) Phase 1 ccRCC data accepted for oral presentation at ESMO 2026; registration-enabling study planned for 2027.
- XmAb541 (CLDN6 x CD3) monotherapy shows ~14% ORR in ovarian, ~28% in germ cell tumors; FDA Fast Track for germ cell; combination with XmAb808 prioritized.
- Cash $486.4M at June 30, 2026; expects year-end 2026 cash $420-440M; sufficient to fund operations through 2028.

## SEC filing metadata
- accession: 0001326732-26-000055
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2026-08-05T20:01:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/0001326732-26-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-26-000055
- JSON: https://secwatch.observer/filing/0001326732-26-000055.json
- Plain text: https://secwatch.observer/filing/0001326732-26-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.